Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: dates

Transgene Announces Rights Issue

20161020 – Capital increase EN FINAL

Published 20 October 2016
Categorized as 2016, Press release

Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition

Patricia Kleinpeter, et al.OncoImmunology, October 2016 – Download the articlePublication

Published 18 October 2016
Categorized as -others, 2016, Invir.IO, Publication

First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients

20161017-tg1050-md-us-final

Published 17 October 2016
Categorized as 2016, Press release, TG1050

Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study

alliance_transgene-collab-press-release_row

Published 11 October 2016
Categorized as 2016, Press release, TG4001

Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities

Johann Foloppe, et al.10th International Meeting on Replicating Oncolytic Virus Therapeutics, Vancouver, Canada – 1-4 October 2016Download the poster herePoster Presentation Collaboration between Transgene – HTS facility IGBMC, Illkirch – France IREBS, Illkirch, France – ICube, Strasbourg, France

Published 5 October 2016
Categorized as -others, 2017, Publication

Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines

20161005-ov-vancouver-vacv-antibody-poster-final-us

Published 5 October 2016
Categorized as 2016, Press release

Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials

20160905 – H1 update – EN – V10

Published 5 September 2016
Categorized as 2016, Press release

Transgene Announces Participation at Upcoming Investor Events

20160901 – Next investor events – EN

Published 1 September 2016
Categorized as 2016, Press release

Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee

20160721 – Safety TG1050 EN Vdef

Published 21 July 2016
Categorized as 2016, Press release, TG1050

Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene

Marine Ricordel, et al. XXI International Poxvirus, Asfavirus and Iridovirus Conference Le Bischenberg (France) 1-5 July 2016 Download the poster here Poster Presentation

Published 1 July 2016
Categorized as -others, 2016, Publication

Posts pagination

Newer posts Page 1 … Page 40 … Page 47 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu